July 6 (Reuters) - Kazia Therapeutics Ltd (KZA) :
- KAZIA'S PAXALISIB RECEIVES FAST TRACK DESIGNATION FROM FDA FOR TREATMENT OF SOLID TUMOR BRAIN METASTASES HARBORING PI3K PATHWAY MUTATIONS IN COMBINATION WITH RADIATION THERAPY
- KAZIA THERAPEUTICS LTD - FURTHER DATA FROM ONGOING PHASE 1 STUDY IS EXPECTED IN 1Q CY2024
News: KZA Kazia's Paxalisib Receives Fast Track Designation From FDA For Treatment Of Solid Tumor...
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
